Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
about
Advances and challenges in malaria vaccine developmentVaccines for preventing malaria (pre-erythrocytic)A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adultsMalaria: progress, perils, and prospects for eradicationThe March Toward Malaria VaccinesSafety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenPlasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trialImpact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection.Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children.Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites.Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.MIG and the regulatory cytokines IL-10 and TGF-β1 correlate with malaria vaccine immunogenicity and efficacy.An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses.The RTS,S vaccine candidate for malaria.Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii.A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hostsAdjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein.Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.Antibody and B cell responses to Plasmodium sporozoites.A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01EEfficacy of Phase 3 Trial of RTS, S/AS01 Malaria Vaccine in infants: a systematic review and meta-analysis.Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations.Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection.Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malariaDaily Plasmodium yoelii infective mosquito bites do not generate protection or suppress previous immunity against the liver stage.A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.Liver-Stage Specific Response among Endemic Populations: Diet and Immunity.The hunt for protective correlates of immunity to Plasmodium falciparum malaria.Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigensImpact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection.A field trial to assess a blood-stage malaria vaccine.Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial.
P2860
Q21032463-45F6F889-F4B6-4D59-9F18-99D040E89979Q24244317-CBB6F71A-D89F-43D6-BD5B-DAB900C7B728Q24804936-0B9529DA-9079-4835-881C-5BF443A57C0EQ27485634-0580159F-9488-4407-A1B3-EA4FE42C21CAQ28084325-C977C709-8E2E-456E-9BEA-3EBB1872C39CQ28744573-1EB11298-F9D2-4BD1-9B1D-56743AC18889Q28748765-A3FD2530-8569-4F0A-9A1C-84B42AA151EDQ30895708-79C66371-7FC0-49DF-A47E-1FDA6BB6F655Q33251913-B35F2086-A415-4985-8729-4F3888625ADDQ33317265-21220CBE-ADA1-48F2-9A5F-E7786A50C844Q33318466-D34BA002-D85E-49D7-AACB-2D05CCE1DDE9Q33430011-37BE56FD-1945-4F64-9A12-9C677D054B98Q33434412-D433DC86-3B80-4EB7-BE53-6E0A2DB27FE1Q33489512-CA66775D-FB4B-494D-A3F8-EDE210CB7A73Q33508230-C04CCC18-DE12-4394-9C39-E679DA26B102Q33515022-C5D95362-C670-4F59-A3FA-B87282A14D64Q33521372-C3B9959B-8644-4768-809C-3F293FE6796EQ33587443-887C3DCE-CAD8-4A46-8B87-DB73F619FA82Q33691320-509453F9-5870-4EC3-84CC-0089C6E21D7CQ33830488-C0128C7D-7A11-4BC0-A503-8B1655F30949Q34186762-AAFE468C-C276-4561-BE40-3667606F65D6Q34258733-0DEFCA0C-F5DA-4D9A-940C-D5F891BBD848Q34261339-13D98314-E16D-4DFC-A0FC-7A89C42C8548Q34274515-91105F10-7935-4562-979F-8AC3C0FCC700Q34301004-B4E08118-A0DB-4E06-AC63-65E028F5BA67Q34530938-93665FFA-F4B9-4178-8069-5CC93ADE9B28Q34541330-DA516956-254C-4C2B-BB6F-3123CFBE186FQ34548672-26C5AF13-58D3-45AD-88A3-579C7B414BBCQ34774547-89BEC6C0-ABF6-4A19-AAD6-90D7A8747AABQ34852105-86752FC4-9107-4EC3-A164-8E99BF12EB4EQ34855814-6033FA47-FF3D-4D15-952B-195523A5099CQ35009202-31918402-3C56-4CDD-9665-B4DD4D73406AQ35073970-C423D77C-D95D-414B-9460-523E1ABD73DAQ35199926-9212F89E-C6B8-4572-B051-1C870FAEABC0Q35304594-FF955CE6-BA82-4295-BC9D-DBDA6C9FAE97Q35330733-853C77CD-D6DD-4738-99B0-F3F8FAFC13EBQ35439859-C7C01AFE-42BC-40E6-9FF3-ECF6E7BCF9E1Q35622737-FB10AB05-4377-45A3-81DD-085BED639C4CQ35684141-C9CD4D00-B990-42EE-88A5-A6DAC0A55796Q35742175-C3D19BD1-50D9-45A2-A07F-1F1784951FE4
P2860
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Efficacy of recombinant circum ...... Plasmodium falciparum malaria.
@en
Efficacy of recombinant circum ...... Plasmodium falciparum malaria.
@nl
type
label
Efficacy of recombinant circum ...... Plasmodium falciparum malaria.
@en
Efficacy of recombinant circum ...... Plasmodium falciparum malaria.
@nl
prefLabel
Efficacy of recombinant circum ...... Plasmodium falciparum malaria.
@en
Efficacy of recombinant circum ...... Plasmodium falciparum malaria.
@nl
P2093
P356
P1476
Efficacy of recombinant circum ...... Plasmodium falciparum malaria.
@en
P2093
C F Ockenhouse
D A McKinney
D G Heppner
J Palensky
K E Kester
M Delchambre
M G Dowler
P304
P356
10.1086/318534
P407
P577
2001-01-24T00:00:00Z